Wound Care Innovations' CellerateRx highlighted at the SuperBones East conference

Jan 20 2010

Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations was highlighted as part of a presentation exhibited at the SuperBones East conference in Nassau, Bahamas, on January 14-17.  The SuperBones Conference has a great reputation for high quality educational lectures and workshops and places top national speakers at the podium.  It was designed to provide a specialty education format that includes vital industry topics and techniques to medical practitioners that specialize in treatment of the lower extremities.

The program included a session entitled “Wound Care for the 21st century” during which one of the speakers, Gary Rothenberg, DPM, CDE, CWS, Director of Resident Training and Attending Podiatrist for the Miami Veterans Administration Healthcare System, highlighted CellerateRX as an effective tool in the management of his patients' complicated diabetic ulcers. His presentation, "Emerging Use of Topical Biologicals: in Limb Salvage: The multimodality Treatment Approach” discussed the role of collagen and its significance in wound healing and highlighted successful case use of CellerateRx.  "We are doing an IRB study using CellerateRx in our facility.  We have seen excellent success when treating the most complicated wounds among our veterans.  It is a product that I have found to be cost and clinically effective.  I look forward to seeing the outcomes from our randomized control trial." stated Dr. Rothenberg.

Cathy Bradshaw, President of Wound Care Innovations, was quoted as saying "As noted in Dr. Rothenberg's presentation, 85% of all LEA (lower extremity amputations) are preceded by non-healing ulcerations. Our product has been shown to successfully address these diabetic wounds."

"We were delighted to once again be a part of this conference, and it was exciting for us to see CellerateRX recognized during the presentations," continued Bradshaw  "Lower extremity wounds and the incidence of amputations is a serious issue in healthcare and we have a product that has been shown to provide quality outcomes in a cost effective manner."

WNDM also announced the completion of sales training for another group of HIRA (Health Industry Representatives Association) reps who will market and sell CellerateRX throughout the United States.  "HIRA brings an additional avenue for market penetration for us throughout the United States," added Bradshaw.  "Our product successfully addresses a complex and costly segment of healthcare."